

14th World Summit on

Alzheimer's Disease, Dementia Care Research and Awareness

6th World Summit on **Heart, Stroke and Neurological Disorders**

August 31- September 01, 2018 | Boston, USA

The emerging role of anticancer-drugs-Bexarotene in a clinical trial of Alzheimer's dementia

Krishna Prasad Pathak

Lord Buddha Academy, Nepal

Background: Cancer is a disease which affects the elderly, just like Alzheimer's disease (AD) which is also a common disease affecting older people. Most of the symptoms are related to both these diseases, therefore there may be the therapeutic link between anticancer drugs and AD.

Objective: To synthesize the studies aimed at therapeutic links between Alzheimer's disease and anticancer drugs (Bexarotene).

Design: To identify potential new treatment possibilities we applied the systematic searches of key electronic databases. The inclusion criteria were;

- a. Studies aimed at improving cancer and anticancer therapies with the human model,
- b. Peer-reviewed and written in English without any searching limitation on the basis of published date,
- c. Studies of drugs related to cancer treatment that was relevant to an AD,
- d. We did not include the clinical news, case report and animal trial studies.

Results: After filtering titles, abstract, references published in English into one study that has been condensed into one volume of literature, However, sufficient studies are conducted with an animal model (mice) and indicating the positive benefits to the AD patients. Bexarotene is useful for the reduction of cholesterol, loss of function associated with APOE ϵ 4, peripheral thyroid hormone metabolism and athyreotic and amyloid beta that is a key cofactor of Alzheimer's disease. Also, Bexarotene has been shown to restore cognitive functions.

Conclusion: This review discusses the emerging role of anticancer-drugs-Bexarotene in a clinical trial of Alzheimer's dementia with the support of animal model successful results and their effectiveness and will be a significant drug in the coming decades.

krishnapathak32@gmail.com